Your Shopping Cart Is Empty
| Report Code: A04878 | Sep 2020 | Pages: 247 | ||
| Tables: 122 | Charts: 53 |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Genetic Testing Market
Request Now !The genetic testing market accounted for $ 12,682 million in 2019, and is expected to reach $ 21,260 million by 2027, registering a CAGR of 10.1% from 2020 to 2027.
Predictive & presymptomatic testing segment is expected to witness a decline as genetic counselors are largely unable to see patients in person, doctors are not available for counselling and laboratories are not able to run the tests due to COVID-19 pandemic.
Genetic tests are defined as medical devices available in the form of kits and panels that are used for testing genetic diseases in humans. Furthermore, the testing is performed by collecting samples of blood from patients. These samples are then run on laboratory machines using test kits. In addition, there are different types of tests used in testing of genetic disorders. For instance, some genetic tests include, predictive & presymptomatic testing, carrier testing, prenatal & newborn testing, diagnostic testing, pharmacogenomic testing, and others. In addition, these tests are used in diagnosis of medical conditions such as cancer diagnosis, genetic disease diagnosis, and cardiovascular disease diagnosis.
The global genetic testing market is expected to register substantial growth in the future, owing to rise in incidences of genetic disorders and cancer and rise in awareness & acceptance of personalized medicines. For instance, genetic testing has been widely used in pharmacogenomics, also referred as drug-gene testing. In addition, advancements in genetic testing techniques are expected to boost the genetic testing market growth during the forecast period. However, standardization concerns of genetic testing-based diagnostics and stringent regulatory requirements for product approvals are anticipated to hamper the genetic testing market growth during the forecast period. Conversely, untapped emerging markets in developing countries are expected to provide remunerative opportunities for the market players. For instance, Healthcare systems in developing countries such as Brazil, India, and China have experienced significant increase in investments in healthcare and infrastructure, which leads to surge in demand for genetic testing in the region.
COVID-19 pandemic has also affected the market adversely. For instance, after COVID-19 was declared as a pandemic by the WHO, countries worldwide adopted lockdowns to observe social distancing as a measure to contain the spread. This led to disruption, limitation, challenges, and changes in each sector of every industry. Similarly, the pandemic has a negative effect on the genetic testing market. This is attributed to the fact that genetic counselors are largely unable to see patients in person, doctors are not available for counselling, and laboratories are not able to run the tests. In addition, governmental bodies such as Centers for Medicaid Services (CMS) presently do not recognize genetic counsellors as healthcare providers and hence, they are not exempted from practicing during lockdowns. Furthermore, clinics reduced face to face genetic counselling to help prevent the spread. However, genetic testing giants such as GeneDx provided an option where they delivered clinician ordered genetic tests. Similarly, clinics and healthcare providers along with patients are now using telehealth as a measure to conduct genetic counselling. In addition, prenatal testing remains least affected out of all types of genetic testing as it is highly essential. For instance, many prenatal genetic counselors reported providing face to face services in the pandemic. Thus, pandemic had an overall negative impact on the genetic testing market.
The global genetic testing market is segmented on the basis of type, technology, application, and region. By type, the genetic testing market size is categorized into predictive & presymptomatic testing, carrier testing, prenatal & newborn testing, diagnostic testing, pharmacogenomic testing, and others. On the basis of technology, it is divided into cytogenetic testing/chromosomal analysis, biochemical testing, and molecular testing. Molecular testing is further classified into DNA sequencing and others. By application, it is segmented into cancer diagnosis, genetic disease diagnosis, cardiovascular disease diagnosis, and others. By region, the genetic testing market size is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
By type, the market is segmented into predictive testing & presymptomatic testing, carrier testing, prenatal & newborn testing, diagnostic testing, pharmacogenomic testing, and others. The prenatal & newborn testing segment held dominant position with highest revenue in 2019, and is expected to maintain its dominance during the forecast period. This is attributable to growth in awareness among people regarding healthcare and increase in incidences of mortality rate from genetic diseases across the world. On the other hand, the pharmacogenomic testing segment is anticipated to witness highest CAGR during the forecast period. This is largely anticipated to increase in application in use of personalized medicine across the globe.
By technology, the molecular testing segment acquired the major genetic testing market share in the year 2019, and is expected to maintain a lead during the forecast period. The growth of this segment is attributed to the fact that molecular testing is the most used technology for genetic testing. For instance, the technology is used in genetic tests such as carrier testing, diagnostic testing, predictive & presymptomatic testing and others. Furthermore, molecular testing is also preferred as it can be used to analyze gains or losses in DNA that are not detectable with routine chromosome analysis.
Region wise, North America was the leading revenue contributor to the global genetic testing market in 2019, and is expected to dominate the market during the forecast period. This is attributed to presence of majority of key players in the region. However, Asia-Pacific is expected to grow at the highest CAGR during the forecast period, owing to increase in affordability, surge in healthcare expenditure, and rise in awareness toward early screening of genetic disorders.
The global genetic testing market is highly competitive and the prominent players in the market have adopted various strategies to garner maximum genetic testing market share. These include collaboration, product launch, partnership, and acquisition. Major players operating in the market include Abbott Laboratories, Bio-Rad Laboratories, Inc. (RainDance Technologies, Inc.), Myriad Genetics, Inc. (Myriad RBM, Inc.), Danaher Corporation (Cepheid), F. Hoffmann-La Roche Ltd., Eurofins Scientific, Illumina, Inc., Qiagen N.V., Thermo Fisher Scientific, Inc., and CSL Ltd.
Key Benefits For Stakeholders
Genetic Testing Market Report Highlights
| Aspects | Details |
|---|---|
| By Type |
|
| By TECHNOLOGY |
|
| By APPLICATION |
|
| By Region |
|
| Key Market Players | BIO-RAD LABORATORIES, INC. (RAINDANCE TECHNOLOGIES, INC.), CSL LTD, QIAGEN N.V. (FORMULATRIX, INC.), MYRIAD GENETICS, INC. (MYRIAD RBM, INC.), EUROFINS SCIENTIFIC, THERMO FISHER SCIENTIFIC, INC, F. HOFFMANN-LA ROCHE LTD, DANAHER CORPORATION (CEPHEID), ABBOTT LABORATORIES, ILLUMINA, INC |
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools & models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning, 2019
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Increase in incidences of genetic disorders and cancer
3.5.1.2.Rise in awareness & acceptance of personalized medicines
3.5.1.3.Advancements in genetic testing techniques
3.5.2.Restraints
3.5.2.1.Standardization concerns of genetic testing-based diagnostics
3.5.2.2.Stringent regulatory requirements for product approvals
3.5.3.Opportunities
3.5.3.1.Untapped emerging markets in developing countries
3.6.Patent analysis (2017–2022)
3.6.1.Patent analysis, by year
3.6.2.Patent analysis for year 2019, by country
CHAPTER 4:GENETIC TESTING MARKET, BY TYPE
4.1.Overview
4.1.1.Market size and forecast, by region
4.2.Predictive & presymptomatic testing
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.3.Carrier testing
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country
4.4.Prenatal and newborn testing
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country
4.5.Diagnostic testing
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country
4.6.Pharmacogenomic testing
4.6.1.Key market trends, growth factors, and opportunities
4.6.2.Market size and forecast, by region
4.6.3.Market analysis, by country
4.7.Others
4.7.1.Key market trends, growth factors, and opportunities
4.7.2.Market size and forecast, by region
4.7.3.Market analysis, by country
CHAPTER 5:GENETIC TESTING MARKET, BY TECHNOLOGY
5.1.Overview
5.1.1.Market size and forecast, by region
5.2.Cytogenetic testing/chromosome analysis
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.3.Biochemical testing
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
5.4.Molecular testing
5.4.1.Market size and forecast, by region, by type
5.4.1.1.DNA Sequencing
5.4.1.1.1.Market size and forecast, by region
5.4.1.2.Others
5.4.1.2.1.Market size and forecast, by region
5.4.2.Market size and forecast, by region
5.4.3.Market analysis, by country
CHAPTER 6:GENETIC TESTING MARKET, BY APPLICATION
6.1.Overview
6.1.1.Market size and forecast
6.2.Cancer diagnosis
6.2.1.Market size and forecast
6.2.2.Market analysis, by country
6.3.Genetic disease diagnosis
6.3.1.Market size and forecast
6.3.2.Market analysis, by country
6.4.Cardiovascular disease diagnosis
6.4.1.Market size and forecast
6.4.2.Market analysis, by country
6.5.Others
6.5.1.Market size and forecast
6.5.2.Market analysis, by country
CHAPTER 7:GENETIC TESTING MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends and opportunities
7.2.2.Market size and forecast, by test type
7.2.3.Market size and forecast, by technology
7.2.4.Market size and forecast, by application
7.2.5.Market size and forecast, by country
7.2.5.1.U.S. market size and forecast, by test type
7.2.5.2.U.S. market size and forecast, by technology
7.2.5.3.U.S. market size and forecast, by application
7.2.5.4.Canada market size and forecast, by test type
7.2.5.5.Canada market size and forecast, by technology
7.2.5.6.Canada market size and forecast, by application
7.2.5.7.Mexico market size and forecast, by test type
7.2.5.8.Mexico market size and forecast, by technology
7.2.5.9.Mexico market size and forecast, by application
7.3.Europe
7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Market size and forecast, by test type
7.3.3.Market size and forecast, by technology
7.3.4.Market size and forecast, by application
7.3.5.Market size and forecast, by country
7.3.5.1.Germany market size and forecast, by test type
7.3.5.2.Germany market size and forecast, by technology
7.3.5.3.Germany market size and forecast, by application
7.3.5.4.France market size and forecast, by test type
7.3.5.5.France market size and forecast, by technology
7.3.5.6.France market size and forecast, by application
7.3.5.7.UK market size and forecast, by test type
7.3.5.8.UK market size and forecast, by technology
7.3.5.9.UK market size and forecast, by application
7.3.5.10.Italy market size and forecast, by test type
7.3.5.11.Italy market size and forecast, by technology
7.3.5.12.Italy market size and forecast, by application
7.3.5.13.Spain market size and forecast, by test type
7.3.5.14.Spain market size and forecast, by technology
7.3.5.15.Spain market size and forecast, by application
7.3.5.16.Rest of Europe market size and forecast, by test type
7.3.5.17.rest of Europe market size and forecast, by technology
7.3.5.18.Rest of Europe market size and forecast, by application
7.4.Asia-Pacific
7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Market size and forecast, by test type
7.4.3.Market size and forecast, by technology
7.4.4.Market size and forecast, by application
7.4.5.Market size and forecast, by country
7.4.5.1.Japan market size and forecast, by test type
7.4.5.2.Japan market size and forecast, by technology
7.4.5.3.Japan market size and forecast, by application
7.4.5.4.China market size and forecast, by test type
7.4.5.5.China market size and forecast, by technology
7.4.5.6.China market size and forecast, by application
7.4.5.7.Australia market size and forecast, by test type
7.4.5.8.Australia market size and forecast, by technology
7.4.5.9.Australia market size and forecast, by application
7.4.5.10.India market size and forecast, by test type
7.4.5.11.India market size and forecast, by technology
7.4.5.12.India market size and forecast, by application
7.4.5.13.South Korea market size and forecast, by test type
7.4.5.14.South Korea market size and forecast, by technology
7.4.5.15.South Korea market size and forecast, by application
7.4.5.16.Rest of Asia-Pacific market size and forecast, by test type
7.4.5.17.Rest of Asia-Pacific market size and forecast, by technology
7.4.5.18.Rest of Asia-Pacific market size and forecast, by application
7.5.LAMEA
7.5.1.Key market trends, growth factors, and opportunities
7.5.2.Market size and forecast, by test type
7.5.3.Market size and forecast, by technology
7.5.4.Market size and forecast, by application
7.5.5.Market size and forecast, by country
7.5.5.1.Brazil market size and forecast, by test type
7.5.5.2.Brazil market size and forecast, by technology
7.5.5.3.Brazil market size and forecast, by application
7.5.5.4.Saudi Arabia market size and forecast, by test type
7.5.5.5.Saudi Arabia market size and forecast, by technology
7.5.5.6.Saudi Arabia market size and forecast, by application
7.5.5.7.South Africa market size and forecast, by test type
7.5.5.8.South Africa market size and forecast, by technology
7.5.5.9.South Africa market size and forecast, by application
7.5.5.10.Rest of LAMEA market size and forecast, by test type
7.5.5.11.Rest of LAMEA market size and forecast, by technology
7.5.5.12.Rest of LAMEA market size and forecast, by application
CHAPTER 8:COMPANY PROFILES
8.1.ABBOTT LABORATORIES
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.2.BIO-RAD LABORATORIES, INC. (RAINDANCE TECHNOLOGIES, INC.)
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance
8.2.6.Key strategic moves and developments
8.3.CSL LTD.
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance
8.4.DANAHER CORPORATION (CEPHEID)
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.4.6.Key strategic moves and developments
8.5.EUROFINS SCIENTIFIC
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance
8.5.6.Key strategic moves and developments
8.6.F. HOFFMANN-LA ROCHE LTD.
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segment
8.6.4.Product portfolio
8.6.5.Business performance
8.6.6.Key strategic moves and developments
8.7.ILLUMINA, INC.
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.8.MYRIAD GENETICS, INC. (MYRIAD RBM, INC.)
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments
8.9.QIAGEN N.V. (FORMULATRIX, INC.)
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segment
8.9.4.Product portfolio
8.9.5.Business performance
8.9.6.Key strategic moves and developments
8.10.THERMO FISHER SCIENTIFIC, INC.
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segment
8.10.4.Product portfolio
8.10.5.Business performance
8.10.6.Key strategic moves and developments
LIST OF TABLES
TABLE 01.GLOBAL GENETIC TESTING MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 02.GLOBAL GENETIC TESTING MARKET FOR PREDICTIVE & PRESYMPTOMATIC TESTING, BY REGION, 2019–2027 ($MILLION)
TABLE 03.GLOBAL GENETIC TESTING MARKET FOR CARRIER TESTING, BY REGION, 2019–2027 ($MILLION)
TABLE 04.GLOBAL GENETIC TESTING MARKET FOR PRENATAL AND NEWBORN TESTING, BY REGION, 2019–2027 ($MILLION)
TABLE 05.GLOBAL GENETIC TESTING MARKET FOR DIAGNOSTIC TESTING BY REGION, 2019–2027 ($MILLION)
TABLE 06.GLOBAL GENETIC TESTING MARKET FOR PHARMACOGENOMIC TESTING, BY REGION, 2019–2027 ($MILLION)
TABLE 07.GLOBAL GENETIC TESTING MARKET FOR OTHER TYPES, BY REGION, 2019–2027 ($MILLION)
TABLE 08.GENETIC TESTING MARKET, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 09.GENETIC TESTING MARKET FOR CYTOGENETIC TESTING, BY REGION, 2019–2027 ($MILLION)
TABLE 10.GENETIC TESTING MARKET FOR BIOCHEMICAL TESTING, BY REGION, 2019–2027 ($MILLION)
TABLE 11.GENETIC TESTING MARKET FOR MOLECULAR TESTING, BY TYPE, 2019–2027 ($MILLION)
TABLE 12.GENETIC TESTING MARKET FOR DNA SEQUENCING, BY REGION, 2019–2027 ($MILLION)
TABLE 13.GENETIC TESTING MARKET FOR OTHER MOLECULAR TESTS, BY REGION, 2019–2027 ($MILLION)
TABLE 14.GENETIC TESTING MARKET FOR MOLECULAR TESTING, BY REGION, 2019–2027 ($MILLION)
TABLE 15.GENETIC TESTING MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 16.GENETIC TESTING MARKET FOR CANCER DIAGNOSIS, BY REGION, 2019–2027 ($MILLION)
TABLE 17.GENETIC TESTING MARKET FOR GENETIC DISEASE DIAGNOSIS, BY REGION, 2019–2027 ($MILLION)
TABLE 18.GENETIC TESTING MARKET FOR CARDIOVASCULAR DISEASE DIAGNOSIS, BY REGION, 2019–2027 ($MILLION)
TABLE 19.GENETIC TESTING MARKET FOR OTHER APPLICATIONS, BY REGION, 2019–2027 ($MILLION)
TABLE 20.GENETIC TESTING MARKET REVENUE, BY REGION, 2019–2027 ($MILLION)
TABLE 21.NORTH AMERICA GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 22.NORTH AMERICA GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 23.NORTH AMERICA GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 24.NORTH AMERICA GENETIC TESTING MARKET REVENUE, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 25.U.S. GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 26.U.S. GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 27.U.S. GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 28.CANADA GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 29.CANADA GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 30.CANADA GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 31.MEXICO GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 32.MEXICO GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 33.MEXICO GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 34.EUROPE GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 35.EUROPE GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 36.EUROPE GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 37.EUROPE GENETIC TESTING MARKET REVENUE, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 38.GERMANY GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 39.GERMANY GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 40.GERMANY GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 41.FRANCE GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 42.FRANCE GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 43.FRANCE GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 44.UK GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 45.UK GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 46.UK GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 47.ITALY GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 48.ITALY GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 49.ITALY GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 50.SPAIN GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 51.SPAIN GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 52.SPAIN GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 53.REST OF EUROPE GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 54.REST OF EUROPE GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 55.REST OF EUROPE GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 56.ASIA-PACIFIC GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 57.ASIA-PACIFIC GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 58.ASIA-PACIFIC GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 59.ASIA-PACIFIC GENETIC TESTING MARKET REVENUE, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 60.JAPAN GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 61.JAPAN GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 62.JAPAN GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 63.CHINA GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 64.CHINA GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 65.CHINA GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 66.AUSTRALIA GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 67.AUSTRALIA GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 68.AUSTRALIA GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 69.INDIA GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 70.INDIA GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 71.INDIA GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 72.SOUTH KOREA GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 73.SOUTH KOREA GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 74.SOUTH KOREA GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 75.REST OF ASIA-PACIFIC GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 76.REST OF ASIA-PACIFIC GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 77.REST OF ASIA-PACIFIC GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 78.LAMEA GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 79.LAMEA GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 80.LAMEA GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 81.LAMEA GENETIC TESTING MARKET REVENUE, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 82.BRAZIL GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 83.BRAZIL GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 84.BRAZIL GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 85.SAUDI ARABIA GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 86.SAUDI ARABIA GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 87.SAUDI ARABIA GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 88.SOUTH AFRICA GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 89.SOUTH AFRICA GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 90.SOUTH AFRICA GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 91.REST OF LAMEA GENETIC TESTING MARKET REVENUE, BY TEST TYPE, 2019–2027 ($MILLION)
TABLE 92.REST OF LAMEA GENETIC TESTING MARKET REVENUE, BY TECHNOLOGY, 2019–2027 ($MILLION)
TABLE 93.REST OF LAMEA GENETIC TESTING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 94.ABBOTT: COMPANY SNAPSHOT
TABLE 95.ABBOTT: OERATING SEGMENT
TABLE 96.ABBOTT: PRODUCT PORTFOLIO
TABLE 97.BIO-RAD: COMPANY SNAPSHOT
TABLE 98.BIO-RAD: OPERATING SEGMENTS
TABLE 99.BIO-RAD: PRODUCT PORTFOLIO
TABLE 100.CSL LTD: COMPANY SNAPSHOT
TABLE 101.CSL LTD..: OPERATING SEGMENT
TABLE 102.CSL LTD..: PRODUCT PORTFOLIO
TABLE 103.DANAHER: COMPANY SNAPSHOT
TABLE 104.DANAHER: OPERATING SEGMENTS
TABLE 105.DANAHER: PRODUCT PORTFOLIO
TABLE 106.EUROFINS SCIENTIFIC: COMPANY SNAPSHOT
TABLE 107.EUROFINS SCIENTIFIC.: PRODUCT PORTFOLIO
TABLE 108.ROCHE: COMPANY SNAPSHOT
TABLE 109.ROCHE: OPERATING SEGMENT
TABLE 110.ROCHE: PRODUCT PORTFOLIO
TABLE 111.ILLUMINA: COMPANY SNAPSHOT
TABLE 112.ILLUMINA: OPERATING SEGMENTS
TABLE 113.ILLUMINA: PRODUCT PORTFOLIO
TABLE 114.MYRIAD: COMPANY SNAPSHOT
TABLE 115.MYRIAD: OPERATING SEGMENTS
TABLE 116.MYRIAD: PRODUCT PORTFOLIO
TABLE 117.QIAGEN: COMPANY SNAPSHOT
TABLE 118.QIAGEN: PRODUCT SEGMENT
TABLE 119.QIAGEN: PRODUCT PORTFOLIO
TABLE 120.THERMO FISHER SCIENTIFIC.: COMPANY SNAPSHOT
TABLE 121.THERMO FISHER SCIENTIFIC: PRODUCT SEGMENT
TABLE 122.THERMO FISHER SCIENTIFIC: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.SEGMENTATION OF GENETIC TESTING MARKET
FIGURE 02.TOP INVESTMENT POCKETS, 2019
FIGURE 03.HIGH BARGAINING POWER OF SUPPLIERS
FIGURE 04.MODERATE BARGAINING POWER OF BUYERS
FIGURE 05.LOW THREAT OF SUBSTITUTION
FIGURE 06.HIGH THREAT OF NEW ENTRANT
FIGURE 07.HIGH COMPETITIVE RIVALRY
FIGURE 08.GLOBAL GENETIC TESTING TOP PLAYER POSITIONING, 2019
FIGURE 09.GLOBAL GENETIC TESTING MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
FIGURE 10.PATENTS REGISTERED/APPROVED IN THE WORLD, 2017-2022
FIGURE 11.PATENTS ANALYSIS BY YEAR, 2017 THROUGH 2022
FIGURE 12.YEAR 2019 PATENT ANALYSIS, BY COUNTRY
FIGURE 13.COMPARATIVE ANALYSIS OF GENETIC TESTING MARKET, BY PREDICTIVE & PRESYMPTOMATIC TESTING, BY REGION, 2019–2027 ($MILLION)
FIGURE 14.COMPARATIVE ANALYSIS OF GENETIC TESTING MARKET, BY CARRIER TESTING, BY REGION, 2019–2027 ($MILLION)
FIGURE 15.COMPARATIVE ANALYSIS OF GENETIC TESTING MARKET, BY PRENATAL AND NEWBORN TESTING, BY REGION, 2019–2027 ($MILLION)
FIGURE 16.COMPARATIVE ANALYSIS OF GENETIC TESTING MARKET, BY DIAGNOSTIC TESTING, BY REGION, 2019–2027 ($MILLION)
FIGURE 17.COMPARATIVE ANALYSIS OF GENETIC TESTING MARKET, BY PHARMACOGENOMIC TESTING, BY REGION, 2019–2027 ($MILLION)
FIGURE 18.COMPARATIVE ANALYSIS OF GENETIC TESTING MARKET, BY OTHER TYPES, BY REGION, 2019–2027 ($MILLION)
FIGURE 19.COMPARATIVE ANALYSIS OF GENETIC TESTING MARKET, BY CYTOGENETIC TESTING, BY REGION, 2019–2027 ($MILLION)
FIGURE 20.COMPARATIVE ANALYSIS OF GENETIC TESTING MARKET, BY BIOCHEMICAL TESTING, BY REGION, 2019–2027 ($MILLION)
FIGURE 21.COMPARATIVE ANALYSIS OF GENETIC TESTING MARKET, BY MOLECULAR TESTING, BY REGION, 2019–2027 ($MILLION)
FIGURE 22.COMPARATIVE ANALYSIS OF GENETIC TESTING MARKET, BY CANCER DIAGNOSIS, BY REGION, 2019–2027 ($MILLION)
FIGURE 23.COMPARATIVE ANALYSIS OF GENETIC TESTING MARKET, BY GENETIC DISEASE DIAGNOSIS, BY REGION, 2019–2027 ($MILLION)
FIGURE 24.COMPARATIVE ANALYSIS OF GENETIC TESTING MARKET, BY CARDIOVASCULAR DISEASE DIAGNOSIS, BY REGION, 2019–2027 ($MILLION)
FIGURE 25.COMPARATIVE ANALYSIS OF GENETIC TESTING MARKET, BY OTHER, BY REGION, 2019–2027 ($MILLION)
FIGURE 26.ABBOTT: NET SALES, 2017–2019 ($MILLION)
FIGURE 27.ABBOTT: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 28.ABBOTT: REVENUE SHARE, BY REGION, 2019(%)
FIGURE 29.BIO-RAD: NET SALES, 2017–2019 ($MILLION)
FIGURE 30.BIO-RAD: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 31.BIO-RAD: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 32.CSL LTD.: NET SALES, 2017–2019 ($MILLION)
FIGURE 33.CSL LTD.: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 34.CSL LTD.: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 35.DANAHER CORPORATION: NET SALES, 2017–2019 ($MILLION)
FIGURE 36.DANAHER CORPORATION: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 37.DANAHER CORPORATION: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 38.EUROFINS SCIENTIFIC.: REVENUE, 2017–2019 ($MILLION)
FIGURE 39.EUROFINS SCIENTIFIC: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 40.ROCHE: NET SALES, 2017–2019 ($MILLION)
FIGURE 41.ROCHE: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 42.ROCHE: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 43.ILLUMINA: NET SALES, 2017–2019 ($MILLION)
FIGURE 44.ILLUMINA: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 45.ILLUMINA: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 46.MYRIAD: NET SALES, 2018–2020 ($MILLION)
FIGURE 47.MYRIAD: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 48.QIAGEN: NET SALES, 2017–2019 ($MILLION)
FIGURE 49.QIAGEN: REVENUE SHARE, BY PRODUCT, 2019 (%)
FIGURE 50.QIAGEN: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 51.THERMO FISHER SCIENTIFIC, INC.: NET SALES, 2017–2019 ($MILLION)
FIGURE 52.THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 53.THERMO FISHER SCIENTIFIC. REVENUE SHARE, BY REGION, 2019 (%)
In accordance with several interviews conducted, applications of genetic testing are anticipated to witness a significant rise with technological advancements, rise in prevalence of genetic diseases, and increase in awareness & acceptance of personalized medicines. As per CXOs, increase in economic strength of developing nations such as Japan, China, India, Indonesia, and Thailand as well as rise in healthcare expenditure are expected to drive the market growth during the forecast period.
Rapid growth was observed in adoption of advanced technology in the healthcare industry across developing economies, and this is expected to offset challenging conditions in mature markets such as North America and Europe. Moreover, Asia-Pacific is expected to grow at the highest CAGR during the forecast period, owing to increase in affordability, surge in healthcare expenditure, and rise in awareness toward early screening of genetic disorders.
A. The total market value of genetic testing market is $12,682 million in 2019.
A. The forecast period for genetic testing market is 2020 to 2027
A. The market value of genetic testing market in 2019 is $10,866 million.
A. The base year is 2019 in genetic testing market
A. Top companies such as, Thermo Fisher Scientific, Inc., Illumina, Inc., F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., Qiagen N.V., and Myriad Genetics, Inc. held a high market position in 2019. These key players held a high market postion owing to the strong geographical foothold in different regions.
A. Prenatal and newborn testing segment is the most influencing segment as newborn testing is very vital and the awareness related to it is on a rise across the globe. In addition, people are also becoming aware about the importance of prenatal testing which leads to surge in demand for prenatal testing across the globe.
A. The major factor that fuels the growth of the global genetic testing market includes increase in incidences of genetic disorders and cancer which leads to surge in demand for genetic testing.
A. Asia-Pacific has the highest growth rate in the market which is growing due to the contribution of the following emerging countries such as China with a CAGR of 14.5%. This is due to increase in healthcare expenditure and technological advancements, with respect to genetic testing.
A. Genetic testing is the study of DNA that identifies gene mutation associated with a variety of genetic disorders.
A. Genetic testing plays a vital role in determining the risk of developing certain diseases as well as screening and sometimes medical treatment.
Start reading instantly.
This Report and over 66,905+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Contact Details
Need to talk to an expert? Book your free consultation and let our research experts help you with your needs/problems.
Global Report 
Regional Report
Country Report
Related Report